Biodel has announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device to treat severe hypoglycemia.
Having previously signed a long-term commercial supply agreement for bulk glucagon, Biodel expects to select a final formulation of its novel glucagon therapy...
According to a series of study results being published in a special issue of Diabetes Care youth with type 2 diabetes experience a more rapid progression of co-morbidities far more aggressive than what is typically seen in adults, even when they receive the best currently available treatment and close monitoring of their condition.
The U.S. FDA has announced that it is allowing marketing of the COBAS INTEGRA 800 Tina-quant HbA1cDx assay (Tina-quant HbA1cDx assay), manufactured by Roche, for the diagnosis of diabetes by health care professionals. This is the first HbA1c test that FDA has allowed to be marketed for this use.
Results of the Novartis-sponsored INTERVAL study have demonstrated the feasibility of setting and achieving individualized treatment targets in elderly patients with type 2 diabetes treated with Novartis drug, Galvus (vildagliptin).
Abbott Diabetes Care has initiated a voluntary recall of FreeStyle lnsulinx Blood Glucose Meters in the United States.
The glucose meters are…
The Greatest Awards Show in Diabetes will be hosted at the House of Blues in San Diego, as the red carpet highlight of Insulindependence’s 2013 conference.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration…
Thanks to the three sisters who write the blog Natural Sweet Recipes, we present you with the perfect frittata!
Mozzarella is one of my favorite…
During Diabetes Blog Week, a week-long event organized by Karen Graffeo of BittersweetDiabetes.com, bloggers sign up to write about a set topic each day for a week. This way, readers can jump around the Diabetes Blog Community and get read different perspectives on a single topic.
JDRF announced today its new executive vice president of research and advocacy, David E. Wheadon, M.D. Dr. Wheadon brings 26 years of experience as a highly effective leader in drug development and translational research, regulatory and medical affairs, and patient advocacy.